One-year follow-up evaluation of magnetic resonance imaging of the brain in dogs with pituitary-dependent hyperadrenocorticism.
OBJECTIVE
To evaluate magnetic resonance imaging (MRI) brain scans of dogs with pituitary-dependent hyperadrenocorticism (PDH) and no signs of CNS dysfunction 1 year after diagnosis and initial MRI.


METHODS
Prospective study of surviving dogs from a previous study.


METHODS
13 dogs underwent MRI of the brain at the time that PDH was diagnosed and prior to treatment. At that time, none of the dogs had clinical signs suggestive of an intracranial mass. Approximately 1 year after diagnosis and MRI, the brain was again evaluated by MRI.


RESULTS
On the initial MRI scan, 5 of the 13 dogs had normal findings, and 8 had evidence of a mass (tumor) in the area of the pituitary gland. Of the 5 dogs that had no visible pituitary mass on the initial MRI scan, 3 had a normal MRI brain scan 1 year later. Of the 5 dogs that had no visible pituitary mass on initial MRI scan, 2 had a visible pituitary mass at 1 year. The 8 dogs that had a visible mass on the initial MRI brain scan had easily identified pituitary masses on the second MRI scan. Of these 8 dogs, 4 had no apparent change in pituitary mass size, and 4 had obvious increase in vertical height of the pituitary mass. Of the 4 dogs, 2 developed signs of neurologic dysfunction within 1 year after diagnosis of PDH, presumably attributable to that mass. Of the 13 dogs, 12 were treated with mitotane soon after completion of the initial MRI scan. Sensitivity to mitotane and initial pituitary mass size or growth were not correlated. Of the 13 dogs evaluated initially and 1 year after diagnosis, 10 had pituitary masses identified on MRI brain scans.


CONCLUSIONS
The incidence of visible pituitary masses among dogs with PDH at the time of or within a year of diagnosis was > 75%. In 2 dogs, signs of CNS dysfunction developed within 1 year of PDH diagnosis when pituitary masses were > or = 10 mm.
Bertoy
E H
EH
Veterinary Medical Teaching Hospital, University of California, Davis 95616, USA.
Feldman
E C
EC
Nelson
R W
RW
Dublin
A B
AB
Reid
M H
MH
Feldman
M S
MS
D000308:Adrenocortical Hyperfunction / Q000209:etiology / Q000662:veterinary*; D000818:Animals; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use; D004283:Dog Diseases / Q000175:diagnosis* / Q000188:drug therapy / Q000209:etiology; D004285:Dogs; D005260:Female; D005500:Follow-Up Studies; D008279:Magnetic Resonance Imaging / Q000662:veterinary*; D008297:Male; D008939:Mitotane / Q000627:therapeutic use; D010911:Pituitary Neoplasms / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy / Q000662:veterinary*; D011446:Prospective Studies
D018931:Antineoplastic Agents, Hormonal; D008939:Mitotane